Halozyme Therapeutics News, Halozyme Therapeutics Quote, HALO Quote

Halozyme Therapeutics (NQ:HALO) Delayed: 67.37 +0.01 (0.01%)

Prev. Close

$67.36

Today 6M 1Y 5Y

Open

$66.80

52 Wk High

$18.39

52 Wk Low

$6.96

Day High

$68.00

Day Low

$66.26

P/E

N/A

EPS

$-0.58

Volume

1,263,287

Friends, Peers and Foes (?): MRK, BMY, MRUS, ABBV, AMGN (more...)

ALERTS | RSS

Mar 6, 2026 08:01 AM FDA approves TECVAYLI and DARZALEX FASPRO combination for multiple myeloma
Mar 6, 2026 08:00 AM U.S. FDA Approves TECVAYLI® in Combination with DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma
Mar 4, 2026 06:56 PM Form 4 HALOZYME THERAPEUTICS, For: Mar 02 Filed by: Torley Helen
Feb 25, 2026 08:30 AM Halozyme to Participate in Upcoming Investor Conferences
Feb 24, 2026 06:19 PM Form 4 HALOZYME THERAPEUTICS, For: Feb 20 Filed by: Caudill Cortney
Feb 24, 2026 06:16 PM Form 4 HALOZYME THERAPEUTICS, For: Feb 20 Filed by: Snyder Mark Howard
Feb 24, 2026 06:15 PM Form 4 HALOZYME THERAPEUTICS, For: Feb 20 Filed by: LaBrosse Nicole
Feb 24, 2026 06:13 PM Form 4 HALOZYME THERAPEUTICS, For: Feb 20 Filed by: Torley Helen
Feb 19, 2026 08:21 AM Halozyme Therapeutics (HALO) PT Raised to $90 at Benchmark Following Strong Q4 Results
Feb 19, 2026 08:13 AM Halozyme Therapeutics (HALO) PT Raised to $94 at Morgan Stanley

Entities mentioned with HALO

View All Entities